

Eff. Date: 2 June 2023 Version: 2.1 IFU: MUC2 ILM4583

# MUC2 (MUCIN-2) clone CCP58

## Instructions for Use

#### Specification:

Recognizes a single glycoprotein of 520kDa, identified as mucin 2 (MUC2). This MAb shows no cross-reaction with human milk fat globule membranes, MUC1, or MUC3. Mucins are high molecular weight glycoproteins, which constitute the major component of the mucus layer that protects the gastric epithelium. MUC2 is specifically expressed in goblet cells of the small intestine & colon; in about 65% of colonic carcinomas and about 40% of gastric carcinomas. MUC2 is rarely expressed outside of the GI tract with the exceptions of mucinous carcinoma of breast and clear cell-type carcinomas of the ovary.

#### Availability:

Catalog No.	Contents	Volume
ILM4583-C01	MUC2	0,1 ml concentrate
ILM4583-C05	MUC2	0,5 ml concentrate
ILM4583-C1	MUC2	1,0 ml concentrate

Intended use: For Research Use Only

Reactivity: Human

Clone: CCP58

Species of origin: Mouse

Isotype: IgG<sub>1/K</sub>

Control Tissue: Small intestine, appendix or colon

Staining: Cytoplasmic, membranous

**Immunogen:** A synthetic peptide of 29 amino acids, KYPTTTPISTTTMVTPTPTGTQTPTTT from MUC2 protein, coupled to KLH

**Presentation:** 200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide

#### Application and suggested dilutions:

Pretreatment: Heat induced epitope retrieval in 10 mM citrate buffer, pH6.0, for 20 minutes is required for IHC staining on formalin-fixed, paraffin embedded tissue sections.

 Immunohistochemical staining of formalin-fixed, paraffin embedded tissue section (dilution 1:50-1:100)

The optimal dilution for a specific application should be determined by the investigator.

**Note:** Dilution of the antibody in 10% normal goat serum followed by a goat anti-mouse secondary antibody-based detection is recommended.

Storage & Stability: Store at 2-8 °C. Do not use after expiration date printed on the vial.

### **References:**

1) Xing PX, *et. al.* Journal of the National Cancer Institute, 1992, 84(9):699-703.

WellMed BV, Delta 52, 6825 MS, Arnhem, The Netherlands



